Chasset F, Ribi C, Trendelenburg M, et al. - In this study, SLE heterogeneity was evaluated by evaluating the expression of three gene sets representative of type I IFN (IFN-I), polymorphonuclear neutrophil (PMN) and plasmablast (PB) signatures in a well-characterized, multidisciplinary cohort of SLE patients. Researchers further tested whether individual gene products could be representative of these three signatures. They collected whole blood, serum and clinical data from 140 SLE individuals. Via NanoString, gene expression was evaluated technology, applying a panel of 37 probes to compute six IFN-I, one PMN and one PB scores. ELISA was used to measure protein levels. High disease activity may be distinguished by IFN-I and PMN gene scores segregate with distinct SLE clinical features, and their combination. MX1 protein level conducted similar to IFN-I gene expression.